A Phase I, Dose-Escalating Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Intrathecal Infusion of KP-100IT through SM-1500 in Subjects with Amyotrophic Lateral Sclerosis (ALS).
Phase of Trial: Phase I
Latest Information Update: 12 May 2016
At a glance
- Drugs Hepatocyte growth factor (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Kringle Pharma
- 13 Jul 2015 Planned number of patients changed from 12 to 15 as per University Hospital Medical Information Network - Japan.
- 11 Mar 2015 According to Kringle Pharm media release, status changed from active, no longer recruiting to completed.
- 16 Jun 2014 Status changed from recruiting to active, no longer recruiting according to the Kingle Pharma media release.